Dyslipidemia and atypical antipsychotic drugs

Daniel Casey

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Dyslipidemia is an increasing problem in most industrialized societies and is a risk factor for coronary heart disease (CHD). Imbalances in individual lipid components, including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and serum triglycerides, have each been shown to contribute to this increased risk. Certain psychiatric patient populations, such as those afflicted with schizophrenia, are of particular concern. Psychiatric patients with schizophrenia are naturally at increased risk for dyslipidemia and obesity, in part due to poor diet and sedentary lifestyle, but these conditions can be exacerbated by some antipsychotic medications. Clozapine and olanzapine, for example, appear to be associated with hyperlipidemia, which may be associated with changes in body weight. Other, newer antipsychotic agents may exhibit less liability for weight gain and the development of dyslipidemia. This review is intended to briefly highlight the association between dyslipidemia and cardiovascular disease, the changes in serum lipids associated with some antipsychotic agents, and how these changes in serum lipids affect the monitoring of schizophrenia patients.

Original languageEnglish (US)
Pages (from-to)27-35
Number of pages9
JournalJournal of Clinical Psychiatry
Volume65
Issue numberSUPPL. 18
StatePublished - 2004

Fingerprint

Dyslipidemias
Antipsychotic Agents
Schizophrenia
olanzapine
Lipids
Psychiatry
Serum
Sedentary Lifestyle
Body Weight Changes
Clozapine
Physiologic Monitoring
Hyperlipidemias
LDL Cholesterol
HDL Cholesterol
Weight Gain
Coronary Disease
Triglycerides
Cardiovascular Diseases
Obesity
Cholesterol

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Dyslipidemia and atypical antipsychotic drugs. / Casey, Daniel.

In: Journal of Clinical Psychiatry, Vol. 65, No. SUPPL. 18, 2004, p. 27-35.

Research output: Contribution to journalArticle

Casey, D 2004, 'Dyslipidemia and atypical antipsychotic drugs', Journal of Clinical Psychiatry, vol. 65, no. SUPPL. 18, pp. 27-35.
Casey, Daniel. / Dyslipidemia and atypical antipsychotic drugs. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. SUPPL. 18. pp. 27-35.
@article{8c9060fd13b94cba8224c5f64daa6933,
title = "Dyslipidemia and atypical antipsychotic drugs",
abstract = "Dyslipidemia is an increasing problem in most industrialized societies and is a risk factor for coronary heart disease (CHD). Imbalances in individual lipid components, including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and serum triglycerides, have each been shown to contribute to this increased risk. Certain psychiatric patient populations, such as those afflicted with schizophrenia, are of particular concern. Psychiatric patients with schizophrenia are naturally at increased risk for dyslipidemia and obesity, in part due to poor diet and sedentary lifestyle, but these conditions can be exacerbated by some antipsychotic medications. Clozapine and olanzapine, for example, appear to be associated with hyperlipidemia, which may be associated with changes in body weight. Other, newer antipsychotic agents may exhibit less liability for weight gain and the development of dyslipidemia. This review is intended to briefly highlight the association between dyslipidemia and cardiovascular disease, the changes in serum lipids associated with some antipsychotic agents, and how these changes in serum lipids affect the monitoring of schizophrenia patients.",
author = "Daniel Casey",
year = "2004",
language = "English (US)",
volume = "65",
pages = "27--35",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 18",

}

TY - JOUR

T1 - Dyslipidemia and atypical antipsychotic drugs

AU - Casey, Daniel

PY - 2004

Y1 - 2004

N2 - Dyslipidemia is an increasing problem in most industrialized societies and is a risk factor for coronary heart disease (CHD). Imbalances in individual lipid components, including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and serum triglycerides, have each been shown to contribute to this increased risk. Certain psychiatric patient populations, such as those afflicted with schizophrenia, are of particular concern. Psychiatric patients with schizophrenia are naturally at increased risk for dyslipidemia and obesity, in part due to poor diet and sedentary lifestyle, but these conditions can be exacerbated by some antipsychotic medications. Clozapine and olanzapine, for example, appear to be associated with hyperlipidemia, which may be associated with changes in body weight. Other, newer antipsychotic agents may exhibit less liability for weight gain and the development of dyslipidemia. This review is intended to briefly highlight the association between dyslipidemia and cardiovascular disease, the changes in serum lipids associated with some antipsychotic agents, and how these changes in serum lipids affect the monitoring of schizophrenia patients.

AB - Dyslipidemia is an increasing problem in most industrialized societies and is a risk factor for coronary heart disease (CHD). Imbalances in individual lipid components, including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and serum triglycerides, have each been shown to contribute to this increased risk. Certain psychiatric patient populations, such as those afflicted with schizophrenia, are of particular concern. Psychiatric patients with schizophrenia are naturally at increased risk for dyslipidemia and obesity, in part due to poor diet and sedentary lifestyle, but these conditions can be exacerbated by some antipsychotic medications. Clozapine and olanzapine, for example, appear to be associated with hyperlipidemia, which may be associated with changes in body weight. Other, newer antipsychotic agents may exhibit less liability for weight gain and the development of dyslipidemia. This review is intended to briefly highlight the association between dyslipidemia and cardiovascular disease, the changes in serum lipids associated with some antipsychotic agents, and how these changes in serum lipids affect the monitoring of schizophrenia patients.

UR - http://www.scopus.com/inward/record.url?scp=16644365958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644365958&partnerID=8YFLogxK

M3 - Article

C2 - 15600382

AN - SCOPUS:16644365958

VL - 65

SP - 27

EP - 35

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 18

ER -